Loading…

Validated RP-HPLC method for the estimation of nebivolol hydrochloride and valsartan in combined tablet dosage form

The intention of this work is to develop a rapid, precise, accurate and sensitive reverse phase liquid chromatographic technique for the simultaneous estimation of Nebivolol and Valsartan in tablet dosage form. The chromatographic method was standardized using Inertsil ODS column (250×4.6mm, 5μm par...

Full description

Saved in:
Bibliographic Details
Published in:Asian Journal of Research in Chemistry 2021-06, Vol.14 (3), p.168-172
Main Authors: Kumar, R. Anantha, Babu, G. Raveendra, M., Sowjanya, M., Ramayyappa
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The intention of this work is to develop a rapid, precise, accurate and sensitive reverse phase liquid chromatographic technique for the simultaneous estimation of Nebivolol and Valsartan in tablet dosage form. The chromatographic method was standardized using Inertsil ODS column (250×4.6mm, 5μm particle size) with UV detection at 278nm and flow rate of 1ml/min. The mobile phase comprises of ACN: Buffer (pH adjusted to 3.5 with dilute Ortho Phosphoric acid) in the fraction of 60:40 v/v. The linearity of proposed method was investigated in the range of 12.5-62.5μg/ml (R²=0.999) for Nebivolol and 200-1000μg/ml(R²=0.999) for Valsartan duly. The limit of detection (LOD) was found to be 0.05μg/ml and 0.81μg/ml for Nebivolol and Valsartan duly. The limit of quantification (LOQ) was found to be 0.15μg/ml and 2.44μg/ml for Nebivolol and Valsartan respectively. The retention time of Nebivolol and Valsartan were ground in to be 4.400min and 2.568min respectively. The method was authentically suggested and % RSD was ground in to be less than 2 indicating high degree of accuracy and precision. Hence proposed method can be successfully graded for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation.
ISSN:0974-4169
0974-4150
DOI:10.52711/0974-4150.2021.00031